Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07781436
Starting soon Not applicable

A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG

NCT07781436 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2026-08-10
Last updated
2026-08-24

Condition(s) studied

CAD - Coronary Artery DiseaseCABGERASMedicine, Chinese Traditional

Investigational drug(s) / intervention(s)

FZYX

FZYX: Intervention: Fuzheng Yangxin Formula granules combined with routine postoperative management. The formula consists of Radix Ginseng 20 g, processed Radix Aconiti Lateralis Preparata 10 g (pre-decocted), Radix Astragali 30 g, Radix Ophiopogonis 20 g, Radix Angelicae Sinensis 15 g, Radix Rehmanniae 15 g, Radix Rhodiolae 30 g, Radix Notoginseng powder 6 g (mixed with warm water for oral use). Participants take the granules orally for 7 consecutive days after CABG.

Study summary

This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.

Eligibility

Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: -Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome. Exclusion Criteria: * Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules. * Patients with fever or common cold after surgery. * Patients with severe postoperative liver and kidney dysfunction. * Patients who receive concurrent valve surgery or other intracardiac operations * Patients with end-stage malignant tumors * Patients with uncontrolled infection or bleeding * Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function * Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.

Primary outcome measure(s)

  • Score of physical activity limitation dimension in the Seattle Angina Questionnaire (SAQ) at 7 days after medication — 7 days after operation
    Measured using the Seattle Angina Questionnaire

Trial sites (1)

FacilityCityRegionStatus
Peking University 3rd hospital Beijing China

More Peking University Third Hospital trials in China

Shared Medical Appointment for COPD Patients (SMA-COPD) Active, not recruiting
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) Recruiting
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison Recruiting
The Cohort Construction Project of Peking University Third Hospital Recruiting
Autologous Osteo-periosteal Cylinder Graft Transplantation for Hepple V Osteochondral Lesions of the Talus Enrolling by invitation

Other trials for the same condition

Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery Recruiting
Low-dose Colchicine for CABG Graft Failure Prevention Starting soon
The Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Chinese Medicine on Gastrointestinal Function Recovery in Patients Undergoing Abdominal Surgery Recruiting
Pilot Trial of Colchicine for Graft Failure in CABG Active, not recruiting
Nonintubated Anesthesia for Adult Cardiac Surgery With Cardiopulmonary Bypass Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07781436 on ClinicalTrials.gov ↗ ← All trials in China